CF Foundation unit backs Pulmatrix program in $1.4M deal; Neuralstem raises $7M;

Conversations on Twitter :

 @FierceBiotech: Neural stem cells partially restore mobility in paralyzed rats. Story | Follow @FierceBiotech

 @RyanMFierce: My conversation with biotech heavy hitter and NEA partner David Mott about investing big in therapeutics startups. Editor's Corner | Follow @RyanMFierce

> An affiliate of the Cystic Fibrosis Foundation has inked a $1.4 million deal with Lexington, MA-based biotech Pulmatrix to fund development of an inhaled drug dubbed PUR118 for treating patients with cystic fibrosis. Release

> Neuralstem ($CUR), a developer of stem cell therapies, has raised $7 million in a direct offering of common stock. Release

> Proteonomix has made a deal with the University of Medicine and Dentristry of New Jersey to execute a Phase I study of the company's candidate UMK-121 for patients with end-stage liver disease. Item

Pharma News

 @FiercePharma: Bayer picks up Teva's animal health biz for $145M. News | Follow @FiercePharma

 @EricPFierce: Health Canada says it will rank drug manufacturing issues by risk of product and by 3 levels of concern. FiercePharmaManufacturing article | Follow @EricPFierce

> U.S. consumers buy more, pay more for drugs. Article

> Mylan may make another acquisition in India. More

> Boehringer Ingelheim lets Facebook game loose. Story

Medical Device News

 @FierceMedDev: Tandem Diabetes Care raked in $36M to further market its super-slim insulin pump. News | Follow @FierceMedDev

 @MarkHFierce: Covidien expects medical device sales to grow 4% to 7% in FY 2013. Release | Follow @MarkHFierce

 @DamianFierce: U.K. engineers have come up with an ultrasound scanner that can made for about $65, targeting developing countries. More | Follow @DamianFierce

> Study: Second life possible for pacemaker harvested from autopsy. Story

> Dx company Response Genetics draws huge GSK investment. Item

And Finally… Amid a NASA rover's mission on Mars, a report questions whether Americans could eventually serve as life on the planet. Article

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.